Harmony Biosciences price to book ratio HRMY

Market value divided by the book value of the company's net assets, since 2020.

Today, Oct 23, 2026: 2.1×
6-year median: 4.0×
Against its 6-year history: 6th; percentile: 0 is its lowest day, 100 its highest
6-year range: 1.8× to 28.7×
Peer median: 3.6×

Harmony Biosciences' price to book ratio is 2.1× as of Oct 23, 2026.

That is below its 6-year median of 4.0×, lower than on 94% of days in the last 6 years.

Over that time it ranged from 1.8× in Mar 2026 to 28.7× in Dec 2020.

The median for 10 large drugmakers of a similar size is 3.6×.

Price to book ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	2.1×	1.8×	2.7×
2025	2.6×	1.9×	3.7×
2024	3.3×	3.1×	4.1×
2023	3.9×	2.4×	9.3×
2022	9.5×	9.5×	16.3×
2021	16.4×	13.7×	24.1×
2020	21.8×	21.5×	28.7×

Against its peers

Companies in Drug Manufacturers - General nearest Harmony Biosciences' size, closest first, today.

Company	Price to book ratio
HRMYHarmony Biosciences	2.1×
PBHPrestige Consumer Healthcare	1.2×
ANIPANI Pharmaceuticals	2.8×
NRIXNurix Therapeutics	2.9×
PAHCPhibro Animal Health	4.1×
ANABAnaptysbio	138×
PCRXPacira BioSciences	2.2×
OGNOrganon	3.6×
OMEROmeros	n/m
LQDALiquidia	19.6×
ARQTArcutis Biotherapeutics	17.8×
Peer median	3.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Harmony Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.